ReiThera, a specialist Italian CDMO in viral vector development and manufacturing, will present five scientific posters and unveil its new US Head of Business Development at the American Society of Gene & Cell Therapy (ASGCT) 2025 Annual Meeting, taking place May 13–17 in New Orleans.

Visitors to booth #545 will get an inside look at ReiThera’s expanding capabilities in scalable gene and cell therapy manufacturing, including upstream and downstream process development, tech transfer, and GMP production. The company’s presence at ASGCT underscores its role as a key partner for biotech and pharma companies advancing genetic vaccines and advanced therapies.

Among the five accepted posters, a standout titled “ReiCell-AAV: A Fully Documented High-Yield Suspension Cell Line for Scalable AAV Vector Manufacturing” will spotlight ReiThera’s proprietary platform developed to boost AAV production efficiency. The new suspension cell line supports high-yield vector manufacturing and is designed for seamless scale-up—addressing growing industry demand for robust, commercially viable gene therapy solutions.

ASGCT 2025 will also mark the debut of Thomas De Maria as ReiThera’s new head of business development, US Based in North America, De Maria brings deep expertise in gene therapy manufacturing and strategic partnerships, positioning him to lead ReiThera’s growth in the US market.

Visitors to the company’s booth #545 will get an inside look at ReiThera’s expanding capabilities in scalable gene and cell therapy manufacturing, including upstream and downstream process development, tech transfer, and GMP production. The company’s presence at ASGCT underscores its role as a key partner for biotech and pharma companies advancing genetic vaccines and advanced therapies.

Among the five accepted posters, a standout titled “ReiCell-AAV: A Fully Documented High-Yield Suspension Cell Line for Scalable AAV Vector Manufacturing” willspotlight ReiThera’s proprietary platform developed to boost AAV production efficiency. The new suspension cell line supports high-yield vector manufacturing and is designed for seamless scale-up – addressing growing industry demand for robust, commercially viable gene therapy solutions.

ASGCT 2025 will also mark the debut of Thomas De Maria as ReiThera’s new head of business Development, US. Based in North America, De Maria brings deep expertise in gene therapy manufacturing and strategic partnerships, positioning him  to lead ReiThera’s growth in the US market. He will be available throughout the meeting to connect with partners and prospective clients.

ReiThera CEO Dr Colloca, though not attending the conference in person, emphasized the importance of the event:“ASGCT is a key moment for our field. Our team’s dedication and technical strength are driving ReiThera’s next phase of growth, and I’m proud of their role in representing us globally.”

ReiThera operates a state-of-the-art GMP facility near Rome, Italy, equipped with stirred-tank bioreactors (50L–2000L), fixed-bed bioreactors for adherent cell growth, a dedicated fill-finish suite, and comprehensive quality control labs. The company offers flexible capacity for clinical and commercial-scale production of viral vectors, including AAV, lentivirus, adenovirus, MVA, and HSV platforms.

“ASGCT is a key moment for our field. Our team’s dedication and technical strength are driving ReiThera’s next phase of growth, and I’m proud of their role in representing us globally.”

ReiThera operates a state-of-the-art GMP facility near Rome, Italy, equipped with stirred-tank bioreactors (50L–2000L), fixed-bed bioreactors for adherent cell growth, a dedicated fill-finish suite, and comprehensive quality control labs. The company offers flexible capacity for clinical and commercial-scale production of viral vectors, including AAV, lentivirus, adenovirus, MVA, and HSV platforms.